Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused biotechs that it has partnered with VC firm Versant Ventures to create another company in a similar mold.

Roche says it’s actively working with its partners to enhance mpox laboratory capacity worldwide to develop diagnostic tests to combat the outbreak.

BioMarin Pharmaceutical is shaking up its leadership team, raiding Amgen for an R&D chief to replace a departing company veteran and pulling off the coup of signing a high-profile former Roche dealmaker.

The FDA has thrown a wrench in Regeneron’s plans to challenge Johnson & Johnson and Pfizer in a blood cancer market, hitting the Big Biotech with a complete response letter over issues at a third-party manufacturer.

Windtree Therapeutics’ roots may have received some urgently needed financial watering last month thanks to a private placement of its stock, but the biotech still doesn’t have enough money to keep its pipeline of cardiovascular meds in health for more than a year.

Pain-medicine-focused Latigo Biotherapeutics is welcoming CRO founder Neil Singla, M.D., aboard as chief medical officer.

Johnson & Johnson said Tuesday it will buy heart failure implant company V-Wave in a deal worth a potential $1.7 billion.

Seattle-based Talus Bioscience has raised $11.2 million in an early fundraising round, money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and help build out the biotech’s drug discovery platform.

As Eli Lilly continues to capitalize on its trove of Mounjaro and Zepbound cash with major outside deals, the company’s early external innovation and collaboration arm, Lilly Catalyze360, is welcoming all comers into the fold.

The FDA granted a green light to its first at-home, over-the-counter test to detect a person’s exposure to syphilis, offering a private option to help detect the sexually transmitted infection.